Most Popular Tests

Apolipoprotein A1 (APO A1) has been reported to be a better predictor than HDL cholesterol and triglycerides for Coronary Artery Disease (CAD). Low levels of APO A1 in serum are associated with increased risk of CAD. The measurement of APO A1 may be of value in identifying patients with atherosclerosis. Apolipoprotein B (APO B) has been reported to be a more powerful indicator of CAD than total cholesterol or LDL cholesterol in angiographic CAD and in survivors of myocardial infarction. In some patients with CAD, APO B is elevated even in the presence of normal LDL cholesterol.

Apolipoprotein B (APO B) has been reported to be a powerful indicator of CAD. In some patients with CAD, APO B is elevated even in the presence of normal LDL cholesterol.

Increased CRP levels are found in inflammatory conditions including: bacterial infection, rheumatic fever, active arthritis, myocardial infarction, malignancies and in the post-operative state. This test cannot detect the relatively small elevations of CRP that are associated with increased cardiovascular risk.

C-Reactive Protein Cardiac (hs CRP) Useful in predicting risk for cardiovascular disease.

Cardio IQ® ASCVD Risk Panel with Score 

This panel provides the 10-year and lifetime risk of atherosclerotic cardiovascular disease (ASCVD) using lipid results with anthropomorphic data and family history. 
The ASCVD risk assessment is recommended in the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

 

 

Cardio IQ® Diabetes Risk Panel with Score - 

Includes
Cardio IQ® Glucose; Cardio IQ® Hemoglobin A1c; Cardio IQ® Cholesterol, Total; Cardio IQ® HDL Cholesterol; Cardio IQ® Triglycerides; Cardio IQ® Non-HDL and Calculated Components; Cardio IQ® 8 Year Diabetes Risk

If Triglyceride is >400 mg/dL, Cardio IQ® Direct LDL will be performed at an additional charge (CPT code(s): 83721).

Clinical Significance

Permit the assessment of serum glucose levels and lipid levels and the prediction of the 8-year future risk of developing diabetes mellitus in patients without diabetes mellitus.

• Assess risk for developing type 2 diabetes mellitus
• Identify lifestyle interventions and/or pharmacotherapy
• This test provides an 8-year risk of developing type 2 diabetes

Type 1 diabetes mellitus is defined as a deficiency of insulin secretion. Type 2 diabetes, which accounts for greater than 90% of all diabetes cases, is caused by a combination of insulin resistance and an inadequate compensatory insulin secretion.

Type 2 diabetes frequently goes undiagnosed, because it has no classic symptoms of diabetes and it progresses slowly from a pre-diabetic state. 

The U.S. Centers for Disease Control and Prevention estimates that 37% of individuals that are greater than 20 years old and approximately  half of those are greater than 65 years old have pre-diabetes. These individuals are at high risk for progression to type 2 diabetes and are candidates for preventive therapy that include lifestyle modification, such as weight  loss, increased physical activity, and medication.

IMPORTANT: For risk calculations to be performed, the following patient-specific information must be provided and recorded at the time of specimen collection:

• Age: Years 
• Gender: M (for male) or F (for female) 
• Height Feet: Feet 
• Height Inches: Inches 
• Weight: lbs 
• Race-African American: Y (for yes) or N (for no) 
• Systolic Blood Pressure: mmHg
• Diastolic Blood Pressure: mmHg
• Treatment for High B.P.: Y (for yes) or N (for no) 
• Diabetes Status: Y (for yes) or N (for no)
• Parental History of Diab: Y (for yes) or N (for no) 
• Smoking Status: Y (for Yes) or N (for no)

This test determines the subtypes of apoe which will aid in the risk assessment of corornary heart disease (CHD) and hyperlipoproteinemia.

Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease.

There are two major forms of Apolipoprotein B, B-100 and B-48. B-100, synthesized in the liver, is the major protein in VLDL, IDL, and LDL cholesterol. B-48, synthesized in the intestines, is essential for the assembly and secretion of chylomicrons. Patients with increased concentrations of Apolipoprotein B are at increased risk of atherosclerosis.

Apolipoprotein A1 is the primary protein associated with HDL cholesterol. Like HDL cholesterol, increased concentrations are associated with reduced risk of cardiovascular disease. Apolipoprotein B-100 is the primary protein associated with LDL cholesterol and other lipid particles. Like LDL cholesterol, increased concentrations are associated with increased risk of cardiovascular disease. The ratio of these two apolipoproteins correlates with risk of cardiovascular disease.

LDL Cholesterol is referred to as the "bad" cholesterol. Interpretive ranges are based on the guidelines of the National Cholesterol Education Program (NCEP).

To assist with control of blood glucose levels, the American Diabetes Association (ADA) has recommended glycated hemoglobin testing (HbA1c) twice a year for patients with stable glycemia, and quarterly for patients with poor glucose control. Interpretive ranges are based on ADA guidelines

An elevated concentration of Homocysteine is an independent risk factor for cardiovascular disease.

Useful in predicting risk of cardiovascular disease.

Insulin is useful in diagnosing hyperinsulinemia in hypoglycemic patients. Hyperinsulinemia may be due to an insulin-producing tumor (insulinoma), syndrome of insulin resistance, or persistent hyperinsulinemic hypoglycemia of infancy.

This is the most common Lipid Panel. Components include those useful in the detection, classification, and monitoring of patients with hyperlipidemia.

Elevated concentrations of Lp(a) are associated with increased risk of coronary artery disease.

There is a correlation between increased risk of premature heart disease with decreasing size of LDL particles. Ion mobility offers the only direct measurement of lipoprotein particle size and concentration for each lipoprotein from HDL3 to large VLDL.

Cardio IQ Lp-PLA2 Activity

Clinical Significance

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor Acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies. The activity assay is an enzyme assay run on an automated chemistry platform.

BNP is used to aid in the diagnosis of left ventricular dysfunction in heart failure. In contrast with BNP, a drug to treat left ventricular dysfunction does not interfere with the measurement of N-terminal pro-BNP.

Measurement of serum 25-OH vitamin D concentrations provide a good index of circulating vitamin D activity in patients not suffering from renal disease. Lower than normal 25-OH vitamin D levels can result from a dietary deficiency, poor abosrption of the vitamin or impaired metabolism of the sterol in the liver. A 25-OH vitamin D deficiency can lead to bone diseases such as rickets and osteomalacia. Above normal levels can lead hypercalcemia. This assay employs liquid chromatography tandem mass spectrometry to independently measure and report the two common forms of 25-hydroxy vitamin D: 25OH D3 - the endogenous form of the vitamin and 25OH D2 - the analog form used to treat 25OH Vitamin D3 deficiency.

Cardio IQ® Lipoprotein Subfractionation, Ion Mobility

Clinical Significance

There is a correlation between increased risk of premature heart disease with decreasing size of LDL particles. Ion mobility offers the only direct measurement of lipoprotein particle size and concentration for each lipoprotein from HDL3 to large VLDL.

Includes

HDL Particle Number; LDL Particle Number; Non-HDL Particle Number; HDL, Small; HDL Large; LDL, Very Small-d; LDL, Very Small-c; LDL, Very Small-b; LDL, Very Small-a; LDL Small; LDL Medium; LDL, Large-b; LDL, Large-a; IDL, Small; IDL, Large; VLDL, Small; VLDL, Medium; VLDL, Large; LDL Pattern; LDL Peak Size

Patient Preparation

Fasting preferred

Methodology

Ion Mobility

 

Chlamydia trachomatis RNA, TMA

Patient Preparation 

Urine specimens: The patient should not have urinated for at least one hour prior to specimen collection. Female patients should not cleanse the labial area prior to providing the specimen.

Urine: Patient should not have urinated within one hour prior to collection. Female patients should not cleanse the labial area prior to providing the specimen. Direct patient to provide a first-catch urine (a maximum of 20-30 mL of the initial urine stream) into a urine collection cup free of any preservatives. 2 mL of urine specimen must be transferred into the APTIMA® specimen transport within 24 hours of collection and before being assayed. Use tube provided in the urine specimen collection kit for urine specimens. The fluid (urine plus transport media) level in the urine tube must fall within the clear pane on the tube labe

Clinical Significance

C. trachomatis infections are the leading cause of sexually transmitted diseases in the united states. C. trachomatis is known to cause cervicitis, pelvic inflammatory disease (PID), epididymitis and proctitis. It is also the most frequent cause of non-gonococcal urethritis in men. Among women, the consequences of chlamydial infections are severe if left untreated. Approximately half of chlamydial infections are asymptomatic.

Chlamydia/Neisseria gonorrhoeae RNA, TMA

Patient Preparation 

Urine specimen: The patient should not have urinated for at least one hour prior to specimen collection. Female patients should not cleanse the labial area prior to providing the specimen.

Urine: Patient should not have urinated within one hour prior to collection. Female patients should not cleanse the labial area prior to providing the specimen. Direct patient to provide a first-catch urine (a maximum of 20-30 mL of the initial urine stream) into a urine collection cup free of any preservatives. 2 mL of urine specimen must be transferred into the APTIMA® specimen transport within 24 hours of collection and before being assayed. Use tube provided in the urine specimen collection kit for urine specimens. The fluid (urine plus transport media) level in the urine tube must fall within the clear pane on the tube label.

 

Clinical Significance

C. trachomatis infections are the leading cause of sexually transmitted diseases in the United States. C. trachomatis is known to cause cervicitis, pelvic inflammatory disease (PID), epididymitis and proctitis. It is also the most frequent cause of non-gonococcal urethritis in men. Among women, the consequences of Chlamydialinfections are severe if left untreated. Approximately half of Chlamydial infections are asymptomatic.
Neisseria gonorrhoeae (gonococci) is the causative agent of gonorrhea. In men, this disease generally results in anterior urethritis accompanied by purulent exudate. In women, the disease is most often found in the cervix, but the vagina and uterus may also be infected.